Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Immunotherapy in treating Alzheimer’s disease

Beka Solomon • 17 Mar 2022
AD/PD 2022
Alzheimer’s Disease Antibodies

Beka Solomon, PhD, Tel Aviv University, Tev Aviv, Israel, discusses immunotherapy in treating Alzheimer’s disease (AD). Prof. Solomon compares healthy individuals to individuals afflicted by AD – stating that natural levels of antibodies against amyloid-β are different between them, suggesting that due to AD patients not having necessary antibodies, immunotherapy could replace the antibodies which could not be developed. This is an excellent opportunity for immunotherapy to help those with AD, yet it could also target neuroinflammation when combined with other treatments. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.

More from Beka Solomon

Inhibition of CXCR4/CXCL12 signaling: a translational perspective for Alzheimer's disease treatment
4:42
Inhibition of CXCR4/CXCL12 signaling: a translational perspective for Alzheimer's disease treatment
Beka Solomon • 17 Mar 2022

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
What are the biological mechanisms underlying the higher prevalence of AD in women?
1:55
What are the biological mechanisms underlying the higher prevalence of AD in women?
Amber Watts • 14 Jul 2026
MenoCog: risk and protective factors for cognitive function in the menopause transition
2:37
MenoCog: risk and protective factors for cognitive function in the menopause transition
Amber Watts • 14 Jul 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals